June 2012

Summaries of ongoing research underway in bladder, prostate, and renal cancer, intended to stimulate discussion about ongoing clinical trials and to promote collaboration across the urology community.

Preliminary data suggest a promising role for sipuleucel-T as a treatment for African-American men with metastatic castration-resistant prostate cancer (mCRPC).

Patients with prostate cancer can expect better sexual function after a robotic-assisted radical prostatectomy (RARP) if they maintain a healthy lifestyle.

In tough economic times when many medical practices have scaled back or even shut down, The Urology Group has flourished.

Spurred by the desire to provide the full spectrum of care to prostate cancer patients, urologists across the country have begun to integrate bone health clinics into their practices.

The implementation of electronic health records to replace paper charts in urology practices is a recent phenomenon that is picking up some serious momentum.

Marital status is an independent predictor of disease-related mortality and overall mortality in men with prostate cancer.

In the last seven years, since the introduction of the targeted therapies, remarkable progress has transpired that has transformed the therapeutic landscape for metastatic renal cell carcinoma.

New data appears to undercut prior research by suggesting that neither NSAIDs nor statins influence the development of renal cell carcinoma.

Enzalutamide seems poised to become an exciting addition to the growing list of novel therapies approved for the treatment of prostate cancer.

As we head into the sweltering days of summer, physicians-and urologists in particular-face a series of challenges that can potentially impact the way we practice and how we manage our patients.